Pioglitazone

Generic Name: Pioglitazone

Brand Names: Actoplus Met, Actos, Duetact, Incresync, Oseni, Tandemact, Pioglitazone Accord, Pioglitazone Actavis

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₀N_₂O_₃S

CAS Number: 111025-46-8

Unique Ingredient Identifier: X4OV71U42S

Background: Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus. It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert in vivo with little consequence. The thiazolidinedione class of medicatio...

Indication: Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also available in combination with metformin, glimepiride, or alogliptin for the same indication.

Associated Conditions: Diabetes, Diabetic Neuropathies, Type 2 Diabetes Mellitus

Associated Therapies: -

Clinical Trials

Triple Therapy in Type 2 Diabetic Patients

Phase 4

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Metformin
Drug: Pioglitazone
Drug: Sitagliptin

First Posted Date: 2013-07-10

Last Posted Date: 2013-07-10

Lead Sponsor: University of Pavia

Target Recruit Count: 64

Registration Number: NCT01895569

Locations: 🇮🇹
IRCCS Policlinico S. Matteo Foundation, Pavia, Italy

Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 Diabetes

Phase 4

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: vildagliptin
Drug: Pioglitazone

First Posted Date: 2013-06-21

Last Posted Date: 2019-03-21

Lead Sponsor: Pusan National University Hospital

Target Recruit Count: 287

Registration Number: NCT01882907

Locations: 🇰🇷
Dong-AUniversity Medical Center, Busan, Korea, Republic of
🇰🇷
Changwon Fatima Hospital, Changwon, Korea, Republic of
🇰🇷
Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of

and more 12 locations

A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas

Phase 2

Completed

Conditions: Cancer of the Pancreas

Interventions: Drug: Pioglitazone

First Posted Date: 2013-04-24

Last Posted Date: 2021-03-01

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 14

Registration Number: NCT01838317

Locations: 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States

Mediators of Abnormal Reproductive Function in Obesity (MARO)

Early Phase 1

Completed

Conditions: Infertility, Female
Obesity

Interventions: Dietary Supplement: Vascepa - Fish Oil
Other: Microdialysis
Drug: Pioglitazone
Drug: Aspirin

First Posted Date: 2013-03-25

Last Posted Date: 2015-03-17

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 10

Registration Number: NCT01817400

Locations: 🇺🇸
University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado, United States

The Impact of Actos Treatment of Diabetes on Glucose Transporters in Muscle

Phase 4

Completed

Conditions: Diabetes Type 2

Interventions: Drug: Pioglitazone
Drug: placebo

First Posted Date: 2013-02-27

Last Posted Date: 2013-02-27

Lead Sponsor: East Tennessee State University

Target Recruit Count: 12

Registration Number: NCT01799850

Locations: 🇺🇸
ETSU Quillen College of Medicine, Johnson City, Tennessee, United States

Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women

Not Applicable

Completed

Conditions: Obesity
Metabolic Syndrome

Interventions: Drug: Pioglitazone
Drug: Placebo

First Posted Date: 2012-12-13

Last Posted Date: 2021-04-30

Lead Sponsor: Pennington Biomedical Research Center

Target Recruit Count: 63

Registration Number: NCT01748994

Locations: 🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States

Pioglitazone for the Treatment of Bipolar Depression

Phase 4

Terminated

Conditions: Bipolar Disorder
Insulin Resistance

Interventions: Drug: Placebo
Drug: Pioglitazone

First Posted Date: 2012-10-30

Last Posted Date: 2017-01-27

Lead Sponsor: University Hospitals Cleveland Medical Center

Target Recruit Count: 37

Registration Number: NCT01717040

Locations: 🇺🇸
University Hospitals Cleveland Medical Center - Mood Disorders Program, Cleveland, Ohio, United States

Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis

Phase 2

Terminated

Conditions: Nonalcoholic Steatohapatitis

Interventions: Drug: Roflumilast
Drug: Placebo
Drug: Pioglitazone

First Posted Date: 2012-10-10

Last Posted Date: 2017-02-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 20

Registration Number: NCT01703260

Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients

Not Applicable

Withdrawn

Conditions: Atopic Dermatitis

Interventions: Drug: Placebo (for pioglitazone)
Drug: Pioglitazone

First Posted Date: 2012-09-28

Last Posted Date: 2014-12-02

Lead Sponsor: University of Rochester

Registration Number: NCT01695707

Locations: 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States

Pioglitazone in Thyroid Cancers

Phase 2

Completed

Conditions: Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene

Interventions: Drug: Pioglitazone

First Posted Date: 2012-08-02

Last Posted Date: 2017-10-26

Lead Sponsor: University of Michigan

Target Recruit Count: 1

Registration Number: NCT01655719

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy